Type 2 immunity to the rescue: enhancing antitumor immunity for skin cancer prevention
- PMID: 39744952
- PMCID: PMC11684797
- DOI: 10.1172/JCI188018
Type 2 immunity to the rescue: enhancing antitumor immunity for skin cancer prevention
Abstract
Cutaneous squamous cell carcinoma (cSCC) incidence and deaths continue to rise, underscoring the need for improved cSCC prevention. Elimination of actinic keratosis (AK) precursor lesions is a major strategy to prevent cSCC. Topical calcipotriol and 5-fluorouracil (5-FU) have been shown to eliminate AKs and reduce the risk of cSCC development, but the mechanism was undefined. In this issue of the JCI, Oka et al. demonstrate that type 2 immunity is necessary and sufficient for the elimination of premalignant keratinocytes and cSCC prevention. Paired biopsies from AK lesions and unaffected skin revealed that only keratinocytes from AKs produced thymic stromal lymphopoietin (TSLP) and damage-associated molecular patterns, resulting in selective recruitment of Th2 cells to the AK lesion. In mouse models of skin carcinogenesis, TSLP was necessary to recruit Th2 cells and trigger IL-24-mediated keratinocyte cell death. These findings suggest that the TSLP/Th2/IL-24 axis is a potential therapeutic target for SCC prevention.
Conflict of interest statement
Figures

Comment on
- T helper 2 cell–directed immunotherapy eliminates precancerous skin lesions
Similar articles
-
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy.J Clin Invest. 2017 Jan 3;127(1):106-116. doi: 10.1172/JCI89820. Epub 2016 Nov 21. J Clin Invest. 2017. PMID: 27869649 Free PMC article. Clinical Trial.
-
T helper 2 cell-directed immunotherapy eliminates precancerous skin lesions.J Clin Invest. 2025 Jan 2;135(1):e183274. doi: 10.1172/JCI183274. J Clin Invest. 2025. PMID: 39744942 Free PMC article.
-
Topical treatment of actinic keratoses in organ transplant recipients: a feasibility study for SPOT (Squamous cell carcinoma Prevention in Organ transplant recipients using Topical treatments).Br J Dermatol. 2022 Sep;187(3):324-337. doi: 10.1111/bjd.20974. Epub 2022 Jun 14. Br J Dermatol. 2022. PMID: 34988975 Free PMC article. Clinical Trial.
-
Use of Topical Calcipotriol Plus 5-Fluorouracil in the Treatment of Actinic Keratosis: A Systematic Review.J Drugs Dermatol. 2022 Jan 1;21(1):60-65. doi: 10.36849/JDD.2022.6632. J Drugs Dermatol. 2022. PMID: 35005863
-
Pharmacotherapy of actinic keratosis: an update.Expert Opin Pharmacother. 2012 Sep;13(13):1847-71. doi: 10.1517/14656566.2012.716039. Expert Opin Pharmacother. 2012. PMID: 22888917 Review.
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials